Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.00-$9.00 vs $8.29 Est; Affirms FY2026 Sales Guidance of $245.000M-$285.000M vs $265.679M Est.
Benzinga Newsdesk 8 months ago
NewsGuidance
Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.00-$9.00 to $8.00-$9.00 vs $8.29 analyst estimate. Affirms FY2026 sales outlook from $245.000 million-$285.000 million to $245.000
Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.00-$9.00 to $8.00-$9.00 vs $8.29 analyst estimate. Affirms FY2026 sales outlook from $245.000 million-$285.000 million to $245.000 million-$285.000 million vs $265.679 million estimate.